IHS Passes Rigorous Audit for World-Wide Distribution of its Insignis™ Infusion System
Innovative Health Sciences (IHS) proudly announces a remarkable milestone in its journey to introduce the Insignis™ Infusion ...
Pharmabiz5 天
BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi
BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...
Finanznachrichten6 天
BioArctic: FDA accepts Biologics License Application for subcutaneous maintenance dosing of ...
If LEQEMBI subcutaneous maintenance dosing is approved by the FDA ... 46 70 410 71 80 About lecanemab (Leqembi ®) Lecanemab is the result of a strategic research alliance between BioArctic and Eisai.